Search

Elasomeran

[L39160, L39277] A similar booster dose is also available in the US for patients 18 years of age and older. … In clinical trials, there were no differences in the safety profiles between younger and older (65 years of age and older) study participants.

Allyl-{4-[3-(4-Bromo-Phenyl)-Benzofuran-6-Yloxy]-but-2-Enyl}-Methyl-Amine

Moxisylyte

[T45] According to the WHO, moxisylyte is approved since 1987[T91] and in the same year, it acquired the denomination of orphan product by the FDA. … Moxisylyte, denominated as thymoxamine in the UK, is a specific and orally active α1-adrenergic antagonist.

Peppermint oil

Peppermint oil is safe and well-tolerated at commonly recommended dosage [A33055]. … Due to its effectiveness in relaxing GI smooth muscle but ability to induce gastroesophageal reflux, enteric-coated formulations of peppermint oil has been established which bypass the upper GI tract unmetabolized

Conjugated estrogens

Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble. … [T475] The conjugated estrogen mixture was approved for marketing in US in 1942 based on the efficacy against certain conditions.

Ondansetron

Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy. … It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Brinzolamide

[A2051] Brinzolamide was approved by the FDA in 1998 as a standalone product and in 2013 as a combination product with brimonidine tartrate.

Amiloxate

Amiloxate is an EMA-approved chemical UV-filter found in over-the-counter sunscreen products at concentrations up to 10%m [F35].

Oxybenzone

It is used as an ingredient in sunscreen and other cosmetics because it absorbs UV-A ultraviolet rays.

Dexlansoprazole

[A19566, A19568, A178084, A174244] Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme.[L48827] … release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing.